Updating on primary fallopian tube carcinoma.
Primary fallopian tube carcinoma (PFTC) is rare, constituting about 1% of female genital tract malignancies, and little is known about its etiological, protective, risk or prognostic factors. Earlier, such factors were thought to be similar to those seen in ovarian cancer. The incidence of PFTC has been rising during the last decades, especially in higher social classes and among women in certain occupations. Parity is a strong protective factor for PFTC, with a lower incidence associated with an increasing number of deliveries. Previous sterilisation seems to offer some protection. Earlier suggestions of previous genital infections as risk factors appear not to hold. Previous cancers are frequent among PFTC patients, especially breast cancer. Second primary cancers after PFTC are also frequent, especially non-lymphoid leukemia, colorectal, breast, bladder and lung cancer. Only 4% of primary fallopian carcinomas are correctly diagnosed before operation. Treatment consists of aggressive cytoreductive surgery and adjuvant chemotherapy with a platinum-taxane combination. A high preoperative serum hCGss is a strong prognostic factor for worse prognosis. The 5-year survival rates vary between 22 and 57%.
Riska
Annika
A
Department of Obstetrics and Gynecology, Helsinki University Central Hospital Area, Hospital District of Helsinki and Uusimaa, Haartmaninkatu 2, Helsinki, Finland. annika.riska@helsinki.fi
Leminen
Arto
A
D000368:Aged; D018394:CA-125 Antigen / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D005185:Fallopian Tube Neoplasms / Q000097:blood / Q000453:epidemiology / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood
D018394:CA-125 Antigen; D006063:Chorionic Gonadotropin; D014359:Trypsin Inhibitor, Kazal Pancreatic